7 completed, 4 terminated, 2 active not recruiting, 1 suspended. 11 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Terminated 4, Active not recruiting 1, Unknown 1 |
| Phase 1 | 8 | Completed 3, Active not recruiting 2, Suspended 1, Terminated 1, Unknown 1 |
Follow IL32 protein, human: new trials by email Literature Review of IL32 protein, human trials Research Report on IL32 protein, human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab Natural Killer Cells, Temozolomide, Irinotecan - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Active not recruiting | Nationwide Children's Hospital | 31 | 2022-09-01 | 2026-09-16 |
| Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells Dinutuximab, NK Cells, Lenalidomide - Neuroblastoma | Phase 1 | Active not recruiting | New Approaches to Neuroblastoma Therapy Consortium | 13 | 2019-01-14 | 2026-03-23 |
| Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia NK Cells + Chemotherapy Starting - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Hospital de Clinicas de Porto Alegre | 30 | 2017-04-01 | 2019-10-15 |
| Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Fludarabine, Cyclophosphamide, NK cells - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 2 | 2014-07-28 | 2017-12-05 |
| Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Allogeneic HCT, Donor NK Cell Infusion - Ewing Sarcoma, Neuroblastoma | Phase 2 | Terminated | Monica Thakar | 15 | 2013-03-20 | 2025-03-19 |
| Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma Humanized anti-GD2 antibody, Chemotherapy, Cytokines - Neuroblastoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 34 | 2012-04-01 | 2018-11-15 |
| NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases Preparative Regimen, NK Cells, Interleukin-2 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 25 | 2011-09-01 | 2020-05-13 |
| Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies Rituximab, Interleukin-2, Natural killer cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 16 | 2010-08-01 | 2018-02-06 |
| Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer Fludarabine, Cyclophosphamide, Cyclosporine - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 13 | 2010-07-01 | 2017-12-28 |
| Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) Natural Killer Cells, Fludarabine, Cyclophosphamide - Leukemia, Myelogenous, Acute | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 15 | 2010-07-01 | 2017-12-28 |
| Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) Epratuzumab, Fludarabine, Cyclophosphamide - Leukemia, Pediatric Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2009-07-01 | 2014-05-22 |
| Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia aldesleukin, allogeneic natural killer cells, rituximab - Leukemia, Lymphoma | Phase 1 / Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 6 | 2008-01-01 | 2017-12-28 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide - Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 21 | 2005-03-01 | 2017-12-28 |
| Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant aldesleukin, natural killer cells, cyclophosphamide - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 50 | 2005-01-01 | 2017-12-28 |
Leukemia, Myeloid, Acute (6) · Neuroblastoma (4) · Leukemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Fallopian Tube Neoplasms (2) · Myelodysplastic Syndromes (2) · Ovarian Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Congenital Abnormalities (1)
Masonic Cancer Center, University of Minnesota (8) · David Wald (1) · Hospital de Clinicas de Porto Alegre (1) · M.D. Anderson Cancer Center (1) · Monica Thakar (1) · Nationwide Children's Hospital (1) · New Approaches to Neuroblastoma Therapy Consortium (1) · St. Jude Children's Research Hospital (1)
United States (14) · Brazil (1)
Melissa Geller, MD (2) · Veronika Bachanova, MD (2) · Anna Franklin, MD (1) · Araz Marachelian, MD, MS (1) · Benjamin Tomlinson, MD (1) · Jeffrey Miller, M.D. (1) · Jeffrey Miller, MD (1) · Jeffrey S. Miller, M.D. (1) · Lucia Silla, Doctor (1) · Mark Ranalli, MD (1) · Monica Thakar, MD (1) · Sarah Cooley, MD (1) · Wayne L. Furman, MD (1)
PMID 24719405, PMID 29218366, PMID 31401903
P01CA065493 (1)